The New Pre-clinical Date of ALN-TMP, an RNAi Therapeutic of Alnylam was Made Public

Recently in the 54th American Society of Hematology Annual Meeting that being held from Dec. 8 to 11, 2012 in Atlanta, Alnylam Pharmaceuticals presented its new pre-clinical data from its RNAi therapeutic program for the treatment of hemoglobinopathies. Its scientists presented related data and showed that ALN-TMP, an RNAi therapeutic targeting Tmprss6, leads to disease modifying effects, including a correction in globin gene expression, in a model of ß-thalassemia. According to Alnylam, these studies were conducted by cooperating with Boston Children’s Hospital.

 

 

Article Link: The New Pre-clinical Date of ALN-TMP, an RNAi Therapeutic of Alnylam was Made Public